LOGIN  |  REGISTER

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 520.81
-11.21 -2.11
3.62M
382.50M
US$ 199.210B
US$ 113.04
-1.95 -1.70
4.17M
1.73B
US$ 195.560B
US$ 542.37
7.08 1.32
889,750
356.18M
US$ 193.180B
US$ 238.20
3.36 1.43
3.44M
722.28M
US$ 172.050B
US$ 361.36
-0.16 -0.04
1.22M
381.22M
US$ 137.760B
US$ 91.29
0.60 0.66
4.78M
1.47B
US$ 134.200B
US$ 79.84
-1.11 -1.37
6.61M
1.28B
US$ 102.200B
US$ 580.43
2.99 0.52
819,434
126.94M
US$ 73.680B
US$ 230.70
2.24 0.98
1.72M
290.01M
US$ 66.910B
US$ 73.54
-0.37 -0.50
3.76M
589.80M
US$ 43.370B
US$ 83.87
-0.19 -0.23
706,103
494.60M
US$ 41.480B
US$ 136.43
0.33 0.24
982,303
285.60M
US$ 38.960B
US$ 199.28
1.89 0.96
1.41M
181.50M
US$ 36.170B
US$ 429.16
13.63 3.28
585,122
81.88M
US$ 35.140B
US$ 235.09
3.42 1.48
749,427
146.80M
US$ 34.510B
US$ 79.88
-1.19 -1.47
3.23M
390.60M
US$ 31.200B
US$ 119.63
0.33 0.28
1.93M
242.01M
US$ 28.950B
US$ 1.00
13.97 1.13
106,971
21.10M
US$ 26.420B
US$ 332.72
-2.84 -0.85
522,898
72.42M
US$ 24.100B
US$ 172.26
4.66 2.78
1.32M
132.02M
US$ 22.740B
US$ 377.10
5.34 1.44
333,771
59.38M
US$ 22.390B
US$ 138.65
2.64 1.94
1.58M
158.60M
US$ 21.990B
US$ 103.59
-0.88 -0.84
1.61M
199.07M
US$ 20.620B
US$ 204.01
-0.11 -0.05
341,888
98.71M
US$ 20.140B
US$ 229.92
0.77 0.34
590,523
83.64M
US$ 19.230B
US$ 268.41
2.11 0.79
511,248
70.14M
US$ 18.830B
US$ 93.01
1.22 1.33
1.14M
199.58M
US$ 18.560B
US$ 215.51
2.23 1.05
528,660
82.56M
US$ 17.790B
US$ 152.27
0.35 0.23
715,583
111.62M
US$ 17.000B
US$ 73.77
0.58 0.79
2.02M
226.94M
US$ 16.740B
US$ 29.66
0.16 0.54
3.98M
510.59M
US$ 15.140B
US$ 115.59
1.99 1.75
727,363
121.70M
US$ 14.070B
US$ 24.64
0.22 0.90
1.69M
435.99M
US$ 10.740B
US$ 57.80
0.55 0.96
1.64M
185.08M
US$ 10.700B
US$ 342.07
2.61 0.77
155,910
31.08M
US$ 10.630B
US$ 44.78
-0.19 -0.42
748,855
222.26M
US$ 9.950B
US$ 189.54
3.74 2.01
629,837
51.14M
US$ 9.690B
US$ 83.93
1.14 1.38
774,728
113.74M
US$ 9.550B
US$ 171.90
0.67 0.39
434,927
53.54M
US$ 9.200B
US$ 60.65
0.92 1.54
1.01M
151.60M
US$ 9.190B
US$ 237.28
-4.69 -1.94
998,753
38.38M
US$ 9.110B
US$ 154.04
4.14 2.76
460,561
56.03M
US$ 8.630B
US$ 155.20
3.75 2.48
562,641
55.14M
US$ 8.560B
US$ 180.49
-1.26 -0.69
457,556
46.44M
US$ 8.380B
US$ 343.47
12.72 3.85
154,666
22.92M
US$ 7.870B
US$ 93.82
2.61 2.86
766,494
69.53M
US$ 6.520B
US$ 17.65
-0.09 -0.51
384,669
352.16M
US$ 6.220B
US$ 40.76
2.51 6.56
4.68M
152.40M
US$ 6.210B
US$ 204.67
5.99 3.01
584,229
29.97M
US$ 6.130B
US$ 96.02
0.13 0.14
653,832
58.28M
US$ 5.600B
US$ 72.75
1.24 1.73
304,679
74.03M
US$ 5.390B
US$ 88.57
4.27 5.07
686,407
54.11M
US$ 4.790B
US$ 133.25
-0.64 -0.48
108,539
33.54M
US$ 4.470B
US$ 35.88
2.12 6.28
3.49M
123.56M
US$ 4.430B
US$ 164.86
4.65 2.90
168,979
24.48M
US$ 4.040B
US$ 78.81
-1.24 -1.55
363,870
50.22M
US$ 3.960B
US$ 65.16
15.39 30.92
8.31M
58.54M
US$ 3.810B
US$ 13.44
-0.19 -1.39
663,042
283.24M
US$ 3.810B
US$ 74.52
-2.36 -3.07
302,088
49.41M
US$ 3.680B
US$ 70.98
0.00 0.00
0
51.12M
US$ 3.630B
US$ 29.66
-0.53 -1.76
785,952
108.20M
US$ 3.210B
US$ 47.61
0.95 2.04
919,389
67.26M
US$ 3.200B
US$ 92.30
1.48 1.63
315,195
31.30M
US$ 2.890B
US$ 48.51
1.18 2.49
349,204
59.36M
US$ 2.880B
US$ 12.73
0.48 3.92
1.89M
216.70M
US$ 2.760B
US$ 26.34
-0.12 -0.45
2.44M
101.66M
US$ 2.680B
US$ 47.55
0.28 0.59
337,988
54.30M
US$ 2.580B
US$ 75.63
6.54 9.47
3.22M
33.56M
US$ 2.540B
US$ 37.36
0.52 1.41
1.27M
65.68M
US$ 2.450B
US$ 51.89
1.37 2.71
482,165
45.69M
US$ 2.370B
US$ 17.69
0.71 4.18
612,898
128.36M
US$ 2.270B
US$ 68.58
0.63 0.93
345,731
30.89M
US$ 2.120B
US$ 92.72
0.98 1.07
199,527
22.48M
US$ 2.080B
US$ 21.70
-1.47 -6.34
828,955
77.16M
US$ 1.670B
US$ 33.49
1.46 4.56
722,424
48.75M
US$ 1.630B
US$ 35.40
-0.44 -1.23
611,343
40.30M
US$ 1.430B
US$ 46.65
0.39 0.84
519,718
28.76M
US$ 1.340B
US$ 9.37
0.00 0.00
953,457
141.77M
US$ 1.330B
US$ 17.12
0.11 0.65
519,841
76.25M
US$ 1.310B
US$ 8.91
-0.28 -3.05
773,288
146.95M
US$ 1.310B
US$ 9.54
-0.10 -1.04
586,815
134.56M
US$ 1.280B
US$ 27.26
0.84 3.18
185,642
46.39M
US$ 1.260B
US$ 23.34
1.01 4.52
531,587
53.63M
US$ 1.250B
US$ 13.78
0.11 0.80
870,365
91.04M
US$ 1.250B
US$ 19.15
-0.48 -2.45
142,317
61.52M
US$ 1.180B
US$ 23.85
-0.69 -2.81
1.09M
49.28M
US$ 1.180B
US$ 23.74
0.06 0.25
325,416
49.60M
US$ 1.180B
US$ 27.84
-0.04 -0.14
231,296
41.92M
US$ 1.170B
US$ 27.49
0.00 0.00
0
40.63M
US$ 1.120B
US$ 13.36
0.30 2.30
562,618
77.11M
US$ 1.030B
US$ 1.45
-0.03 -2.03
5.45M
672.80M
US$ 975.560M
US$ 10.76
-0.17 -1.56
353,371
83.72M
US$ 900.830M
US$ 6.79
-0.04 -0.59
435,397
128.81M
US$ 874.620M
US$ 29.36
0.75 2.62
369,815
28.01M
US$ 822.370M
US$ 459.92
0.00 0.00
0
1.76M
US$ 809.460M
US$ 4.23
0.17 4.19
4.17M
186.64M
US$ 789.490M
US$ 15.64
0.09 0.58
635,722
45.96M
US$ 718.810M
US$ 56.49
0.97 1.75
15,478
12.67M
US$ 715.730M
US$ 17.43
0.08 0.46
148,391
38.21M
US$ 666.000M
US$ 19.67
0.22 1.13
532,911
33.60M
US$ 660.910M
US$ 1.77
-0.05 -2.75
909,457
372.26M
US$ 658.900M
US$ 4.13
-0.16 -3.73
62.14M
155.96M
US$ 644.110M
US$ 9.83
-0.61 -5.84
472,738
65.37M
US$ 642.590M
US$ 14.56
-1.55 -9.62
852,866
44.01M
US$ 640.790M
US$ 14.50
0.24 1.68
273,438
41.10M
US$ 595.950M
US$ 14.12
-0.15 -1.05
218,746
41.94M
US$ 592.190M
US$ 1.99
0.00 0.00
9.53M
294.32M
US$ 585.700M
US$ 9.97
0.72 7.78
9.30M
58.52M
US$ 583.440M
US$ 23.77
0.42 1.80
108,091
24.22M
US$ 575.710M
US$ 8.87
0.92 11.57
72,852
64.80M
US$ 574.780M
US$ 18.78
0.02 0.11
155,445
30.59M
US$ 574.480M
US$ 39.71
0.19 0.48
136,727
14.29M
US$ 567.460M
US$ 58.94
-0.10 -0.17
423,909
9.27M
US$ 546.370M
US$ 7.79
-0.11 -1.39
272,856
62.30M
US$ 485.320M
US$ 11.87
-0.21 -1.74
346,007
38.52M
US$ 457.230M
US$ 4.30
-0.09 -2.05
351,931
105.48M
US$ 453.560M
US$ 17.52
-0.01 -0.06
170,268
24.00M
US$ 420.480M
US$ 17.67
-0.06 -0.34
84,862
23.48M
US$ 414.890M
US$ 12.66
-0.01 -0.08
264,788
31.97M
US$ 404.740M
US$ 14.03
0.04 0.29
78,140
27.60M
US$ 387.230M
US$ 9.27
0.19 2.09
785,593
40.63M
US$ 376.640M
US$ 9.87
0.72 7.87
151,179
37.43M
US$ 369.430M
US$ 13.65
0.41 3.10
153,442
26.22M
US$ 357.900M
US$ 11.93
0.36 3.11
91,442
29.85M
US$ 356.110M
C$ 2.24
0.00 0.00
0
154.17M
C$ 345.340M
US$ 13.47
-0.17 -1.25
129,235
24.26M
US$ 326.780M
US$ 4.75
0.30 6.74
1.66M
68.42M
US$ 325.000M
US$ 7.96
-0.16 -1.97
90,545
38.94M
US$ 309.960M
US$ 33.81
0.31 0.93
18,716
8.74M
US$ 295.500M
US$ 0.48
-0.03 -5.06
20.13M
595.33M
US$ 282.780M
US$ 3.74
0.05 1.36
745,427
74.59M
US$ 278.970M
US$ 31.23
0.54 1.76
106,453
8.46M
US$ 264.210M
US$ 6.69
0.14 2.14
110,446
39.49M
US$ 264.190M
US$ 8.08
-0.01 -0.12
42,795
31.85M
US$ 257.350M
US$ 7.70
-0.32 -3.99
137,308
32.80M
US$ 252.560M
US$ 3.53
0.02 0.57
1.29M
67.59M
US$ 238.590M
US$ 7.83
0.04 0.51
47,252
30.03M
US$ 235.130M
US$ 6.83
0.24 3.64
589,276
33.70M
US$ 230.170M
US$ 9.51
-0.11 -1.14
158,116
23.82M
US$ 226.530M
US$ 2.64
0.27 11.39
918,842
84.73M
US$ 223.690M
US$ 2.19
0.12 5.80
1.05M
100.56M
US$ 220.230M
US$ 1.45
-0.03 -2.03
595,020
145.47M
US$ 210.930M
US$ 60.89
-0.46 -0.75
13,765
3.39M
US$ 206.420M
US$ 23.50
1.50 6.82
6,970
8.53M
US$ 200.460M
US$ 57.78
10.79 22.96
75,676
3.26M
US$ 188.360M
US$ 4.00
0.10 2.56
176,068
45.84M
US$ 183.360M
US$ 9.56
-0.18 -1.85
60,672
18.81M
US$ 179.820M
US$ 8.32
0.11 1.34
83,046
21.26M
US$ 176.880M
US$ 5.40
0.37 7.36
1.13M
32.02M
US$ 172.910M
US$ 3.40
-0.09 -2.58
232,843
50.40M
US$ 171.360M
C$ 0.57
0.02 3.64
100,670
282.82M
C$ 161.210M
US$ 5.04
0.02 0.40
12,725
30.49M
US$ 153.670M
US$ 0.92
-0.09 -8.91
301,626
156.55M
US$ 144.030M
US$ 3.80
0.09 2.43
374,567
37.47M
US$ 142.390M
US$ 2.99
-0.06 -1.97
255,782
43.09M
US$ 128.840M
US$ 2.47
0.04 1.65
70,117
49.56M
US$ 122.410M
US$ 7.24
-0.01 -0.14
250,666
16.39M
US$ 118.660M
US$ 17.99
0.63 3.63
174,516
6.55M
US$ 117.830M
US$ 2.35
0.03 1.29
60,597
49.50M
US$ 116.320M
US$ 2.84
-0.07 -2.41
47,767
39.39M
US$ 111.870M
US$ 3.46
0.01 0.29
68,955
30.25M
US$ 104.660M
US$ 8.50
-0.15 -1.73
79,584
11.61M
US$ 98.680M
US$ 15.34
0.32 2.13
8,344
6.27M
US$ 96.180M
US$ 2.19
0.05 2.34
212,334
43.62M
US$ 95.530M
US$ 0.35
0.00 0.00
0
272.84M
US$ 94.920M
US$ 2.54
0.05 1.89
51,481
37.10M
US$ 94.120M
US$ 2.57
0.17 7.08
63,386
34.31M
US$ 88.180M
US$ 1.57
0.08 5.37
273,085
55.65M
US$ 87.370M
US$ 16.00
1.39 9.51
171,597
5.25M
US$ 84.000M
US$ 1.02
0.07 7.37
368,150
77.89M
US$ 79.450M
C$ 0.31
0.02 6.90
440,070
247.78M
C$ 76.810M
US$ 2.20
-0.09 -3.93
329,531
34.82M
US$ 76.600M
US$ 1.37
0.07 5.38
683,215
55.50M
US$ 76.040M
US$ 1.28
0.00 0.00
317,662
59.23M
US$ 75.810M
US$ 4.55
0.00 0.00
37,646
16.04M
US$ 72.980M
US$ 2.77
0.06 2.21
38,367
26.08M
US$ 72.240M
US$ 3.78
-0.01 -0.26
157,643
19.01M
US$ 71.860M
US$ 0.51
-0.01 -2.66
52,918
139.01M
US$ 71.310M
US$ 1.27
-0.13 -9.29
7.35M
52.54M
US$ 66.730M
US$ 1.72
0.06 3.61
30,742
37.64M
US$ 64.740M
US$ 3.50
0.00 0.00
0
17.86M
US$ 62.510M
US$ 0.64
-0.03 -5.00
38,293
95.97M
US$ 61.320M
US$ 2.27
0.03 1.34
242,905
26.67M
US$ 60.540M
US$ 3.44
0.08 2.38
184,236
17.54M
US$ 60.340M
US$ 7.05
0.00 0.00
5,544
8.53M
US$ 60.140M
US$ 5.63
-0.02 -0.35
6,081
10.64M
US$ 59.900M
US$ 3.39
-0.19 -5.31
174,775
17.64M
US$ 59.800M
US$ 1.03
-0.03 -2.83
340,769
57.89M
US$ 59.630M
US$ 0.14
0.02 20.85
2.30M
417.59M
US$ 59.300M
US$ 1.04
0.10 11.04
2.71M
54.95M
US$ 57.150M
US$ 1.40
-0.05 -3.45
66,685
40.14M
US$ 56.200M
US$ 2.60
-0.40 -13.33
2.04M
20.75M
US$ 53.950M
US$ 1.80
-0.02 -1.10
4,321
29.25M
US$ 52.650M
US$ 19.66
0.00 0.00
19,271
2.53M
US$ 49.740M
US$ 0.83
0.005 0.61
300,056
59.34M
US$ 48.960M
C$ 0.43
0.005 1.18
144,750
113.40M
C$ 48.760M
US$ 2.81
0.67 31.31
62.78M
16.93M
US$ 47.570M
US$ 3.13
0.07 2.29
437,948
13.30M
US$ 41.630M
US$ 1.03
0.00 0.00
121,290
37.72M
US$ 38.850M
US$ 0.72
-0.01 -1.90
55,782
52.24M
US$ 37.720M
C$ 0.31
-0.02 -6.06
10,250
119.77M
C$ 37.130M
C$ 0.48
0.07 15.85
232,070
77.42M
C$ 36.770M
US$ 5.54
2.43 78.14
6,807
6.63M
US$ 36.740M
C$ 0.39
-0.03 -7.14
31,400
93.38M
C$ 36.420M
C$ 0.32
-0.005 -1.54
62,840
113.10M
C$ 36.190M
US$ 1.04
0.12 13.04
331,788
30.84M
US$ 32.070M
US$ 1.00
0.22 28.21
1.82M
31.93M
US$ 31.930M
US$ 1.56
0.008 0.52
25,587
20.24M
US$ 31.530M
US$ 1.22
-0.13 -9.63
36,504
25.04M
US$ 30.550M
US$ 0.85
-0.04 -4.79
310,987
34.10M
US$ 29.050M
US$ 1.69
-0.08 -4.52
54,584
16.64M
US$ 28.120M
US$ 1.02
0.08 9.04
471,331
27.52M
US$ 28.070M
US$ 0.27
-0.05 -15.69
31.18M
101.99M
US$ 27.230M
US$ 0.37
0.01 3.89
2.53M
72.19M
US$ 27.000M
US$ 3.03
0.37 13.98
4.09M
8.81M
US$ 26.710M
US$ 1.12
0.00 0.00
70,661
22.90M
US$ 25.650M
US$ 1.45
-0.13 -8.23
111,419
17.23M
US$ 24.980M
US$ 3.66
-0.17 -4.44
172,215
6.79M
US$ 24.850M
US$ 4.24
-0.13 -2.97
226,411
5.54M
US$ 23.490M
US$ 0.75
-0.05 -6.42
101,665
29.94M
US$ 22.340M
C$ 0.07
0.005 7.69
7,000
270.17M
C$ 18.910M
US$ 1.00
-0.03 -2.91
151,864
18.50M
US$ 18.500M
C$ 0.08
0.005 6.67
28,000
217.73M
C$ 17.420M
C$ 0.19
0.00 0.00
0
90.89M
C$ 17.270M
US$ 0.77
0.04 5.48
39.60M
22.00M
US$ 16.940M
C$ 0.11
0.00 0.00
91,500
159.67M
C$ 16.770M
US$ 1.59
0.05 3.25
13,303
10.54M
US$ 16.760M
US$ 0.78
0.01 1.34
28,792
20.86M
US$ 16.270M
C$ 0.04
-0.005 -12.50
415,684
451.63M
C$ 15.810M
US$ 2.67
0.00 0.00
0
5.89M
US$ 15.730M
US$ 0.97
0.03 3.19
96,547
15.58M
US$ 15.110M
C$ 0.05
0.00 0.00
136,391
320.55M
C$ 14.420M
US$ 2.17
0.00 0.00
0
6.24M
US$ 13.540M
US$ 0.93
0.13 16.25
4.46M
13.96M
US$ 12.980M
US$ 1.94
0.74 61.67
54.38M
6.67M
US$ 12.940M
US$ 0.63
0.15 30.17
19.40M
20.19M
US$ 12.720M
US$ 3.05
-0.01 -0.33
3,685
4.17M
US$ 12.720M
US$ 0.24
0.0086 3.72
6.26M
52.29M
US$ 12.550M
US$ 0.75
0.03 4.17
54,030
16.67M
US$ 12.500M
C$ 0.13
0.00 0.00
132,350
100.02M
C$ 12.500M
US$ 0.37
0.0097 2.69
205,967
31.90M
US$ 11.800M
US$ 5.07
0.69 15.75
153,812
2.22M
US$ 11.260M
US$ 0.40
-0.01 -3.47
6,355
24.39M
US$ 9.760M
US$ 0.33
0.00 0.00
0
29.00M
US$ 9.430M
US$ 0.93
-0.97 -51.05
3,182
10.07M
US$ 9.370M
US$ 2.08
-0.02 -0.95
140,092
4.46M
US$ 9.280M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.870M
US$ 5.89
0.34 6.13
32,455
1.48M
US$ 8.720M
C$ 0.15
0.00 0.00
119,000
59.81M
C$ 8.670M
US$ 0.41
0.00 0.00
955,388
21.04M
US$ 8.630M
US$ 1.40
-0.37 -20.90
1.95M
5.85M
US$ 8.190M
US$ 3.97
0.04 1.12
11,533
2.04M
US$ 8.100M
US$ 0.49
0.03 7.15
666,489
15.37M
US$ 7.490M
US$ 0.64
-0.03 -4.46
388,512
11.07M
US$ 7.120M
US$ 2.20
0.02 0.92
117,403
3.14M
US$ 6.910M
C$ 0.11
0.00 0.00
56,182
59.60M
C$ 6.560M
US$ 1.46
-0.02 -1.35
91,075
4.39M
US$ 6.410M
US$ 0.36
0.02 6.44
694,404
16.82M
US$ 6.090M
C$ 0.06
-0.005 -8.33
58,000
101.29M
C$ 5.570M
US$ 1.18
0.00 0.00
209,446
4.37M
US$ 5.160M
US$ 0.22
0.01 6.51
36.36M
23.46M
US$ 5.110M
C$ 0.04
0.00 0.00
0
122.72M
C$ 4.910M
C$ 0.05
0.00 0.00
0
96.48M
C$ 4.820M
US$ 0.39
0.00 0.00
0
11.88M
US$ 4.630M
US$ 2.20
-0.02 -0.90
41,965
2.05M
US$ 4.510M
US$ 0.56
0.03 5.66
3.45M
8.00M
US$ 4.480M
US$ 3.65
-0.01 -0.27
13,867
980,321
US$ 3.580M
US$ 6.48
-0.20 -3.00
37,104
536,908
US$ 3.480M
US$ 0.47
0.03 7.14
1.59M
7.26M
US$ 3.380M
US$ 1.79
-0.21 -10.50
1,598
1.82M
US$ 3.260M
US$ 2.96
0.06 2.07
345,989
962,637
US$ 2.850M
US$ 1.15
0.04 3.60
409,255
2.46M
US$ 2.830M
US$ 0.73
0.04 5.29
182,363
3.73M
US$ 2.720M
US$ 0.25
0.00 0.00
0
10.59M
US$ 2.650M
US$ 0.32
-0.03 -9.79
831,725
8.27M
US$ 2.630M
US$ 0.78
0.00 0.00
0
3.37M
US$ 2.630M
US$ 0.70
0.10 15.81
59.83M
3.75M
US$ 2.610M
US$ 0.77
-0.04 -5.13
461,609
3.20M
US$ 2.460M
US$ 0.03
0.00 0.00
0
96.71M
US$ 2.420M
C$ 0.05
0.00 0.00
0
48.23M
C$ 2.410M
US$ 3.73
-0.73 -16.37
111,599
552,854
US$ 2.060M
US$ 0.05
-0.04 -42.22
16,199
29.91M
US$ 1.560M
US$ 0.12
-0.0012 -0.99
1,100
7.26M
US$ 871K
US$ 0.15
0.00 0.00
0
5.24M
US$ 796K
US$ 1.83
0.00 0.00
0
418,049
US$ 765K
US$ 0.40
0.00 0.00
0
1.78M
US$ 712K
US$ 0.85
0.00 0.00
60,097
-
US$ -
US$ 0.00
0.00 0.00
0
40.35M
US$ -
US$ 0.00
0.00 0.00
0
15.85M
US$ -
US$ 0.00
-0.17 -100.00
260
6.39M
US$ -
US$ 0.00
-0.0004 -100.00
20,000
855.04M
US$ -
US$ 6.06
0.00 0.00
16,151
-
US$ -
US$ 26.53
0.00 0.00
110,815
-
US$ -
C$ 0.75
0.00 0.00
6,100
-
C$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest News From Medical Stocks


Teleflex to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WAYNE, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor section of the Teleflex website at... Read more


Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously established performance of the Nodify CDT® blood-based lung nodule test. Clinical data is one of the foundational pillars driving the success of Biodesix through market adoption and payor coverage... Read more


West Pharmaceutical Services to Present at the CJS 25th Annual "New Ideas for the New Year" Investor Conference

EXTON, Pa., Jan. 6, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that Cindy Reiss-Clark, Sr. VP and Chief Commercial Officer; Chad Winters, VP of Finance and Chief Accounting Officer; and John Sweeney, VP of Investor Relations, will present at the CJS 25th Annual "New Ideas for the New Year" Virtual Investor Conference on January 14, 2025 at 10:15 a.m.... Read more


Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference

GALWAY, Ireland, Jan. 6, 2025 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual J.P. Morgan healthcare conference on Monday, January 13, 2025. Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation and answer questions on the company beginning at 2:15 p.m. PST (4:15 p.m. CST). Immediately following the presentation, Martha will be joined by other Medtronic... Read more


Danaher to Present at J.P. Morgan Healthcare Conference

WASHINGTON, Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANA... Read more


Stryker announces definitive agreement to acquire Inari Medical, providing entry into high-growth peripheral vascular segment

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position... Read more


Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

With this approval, all of the tests in Castle’s dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the state of New York FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the New York State Department of Health (NYSDOH)... Read more


Apyx Medical Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

CLEARWATER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System. The AYON Body Contouring System was developed with a focus... Read more


NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications  NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that it is expanding... Read more


Outset Medical Announces $169 Million Private Placement Financing From Leading Mutual Funds and Healthcare Institutional Investors

Secures New Debt Financing of up to $125M Maturing in 2030 with Plans to Retire $200M in Prior Debt Reports Unaudited Fourth-Quarter Revenue of $29 million and 2024 Revenue of $113 million SAN JOSE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it has entered into a definitive securities... Read more


Avanos Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ALPHARETTA, Ga., Jan. 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will present at the 43rd  Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, Jan. 13, at approximately 3:45 p.m. PST. A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site. About... Read more


Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco. Zhenya Lindgardt, President and CEO, will present on January 16 at 9:45 a.m.... Read more


Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time. The public may access Mr. Simon's presentation live via audio webcast by clicking here. The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website.... Read more


Bionano Genomics Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of... Read more


Sotera Health Appoints Vincent K. Petrella as Lead Independent Director

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company’s Board of Directors since 2020, brings a wealth of experience... Read more


Bionano Genomics Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common... Read more


Intuitive Announces Executive Leadership Changes to Support Continued Global Growth

SUNNYVALE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced executive leadership promotions in support of the company’s continued global growth in pursuit of its mission to advance minimally invasive care. Henry Charlton has been promoted to the role of executive vice president and chief commercial and marketing officer. A 21-year Intuitive... Read more


Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

MIAMI / Jan 03, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Pulse Biosciences’ Management is scheduled to present on Wednesday, January 15, 2025, at 3:45 pm PT. A live and recorded webcast of the presentation will be available... Read more


Paragon 28 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ENGLEWOOD, Colo. / Jan 03, 2025 / Business Wire / Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. A live webcast, as well as the archived... Read more


European Patent Office Issues Intention to Grant Notice to IceCure Medical for its Next-Generation Cryoablation Technology

XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel, Jan. 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received an Intention... Read more


ICU Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN CLEMENTE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- ICU Medical (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ICU Medical’s presentation will be on Wednesday, January 15, 2025 at 10:30 a.m. PT (1:30 p.m. ET). Company management will also be participating... Read more


Thermo Fisher Scientific to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

WALTHAM, Mass. / Jan 03, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo... Read more


Inari Medical to Present at the J.P. Morgan Healthcare Conference

IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other vascular diseases, announced today that its management team is scheduled to present at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 8:15 a.m. Pacific Time. Interested parties may access a live webcast and replay of the presentation by visiting the Inari... Read more


CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood... Read more


Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

BAAR, Switzerland / Jan 03, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be joined by Christoph Brackmann, Chief Financial Officer, for one-on-one meetings... Read more


NeuroOne Medical Technologies Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST

Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will hold a virtual roadshow webinar to discuss its business operations... Read more


Quanterix to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass. / Jan 02, 2025 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13th-16th at the Westin St. Francis Hotel in San Francisco, CA. Quanterix’s presentation will be on Wednesday, January 15, 2025, at 4:30 p.m.,... Read more


Treace Medical Concepts to Present at 43rd Annual J.P. Morgan Healthcare Conference

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference... Read more


CONMED to Present at the J.P. Morgan Healthcare Conference

LARGO, Fla. / Jan 02, 2025 / Business Wire / CONMED Corporation (NYSE: CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan Healthcare Conference at 4:30 p.m. PT (7:30 p.m. ET) on Monday, January 13, 2025 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the “Investors” section of the Company’s... Read more


RxSight to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference. RxSight’s management is scheduled to present on Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. Interested parties may access a live... Read more


PacBio to Present at 43rd Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the... Read more


Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the... Read more


Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in healthcare dedicated investment with a track record of success in medicine, partnerships, and research. With over 20 years of investment experience in public and private life science companies, Dr. Wirk is the founder and Chief Investment... Read more


QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO / Dec 31, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference. The Company’s presentation is scheduled for Monday, January 13, 2025 at 7:30 a.m. PST / 10:30 a.m. EST.... Read more


Penumbra to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Event:     43rd Annual J.P. Morgan Healthcare ConferenceDate:       Monday, January 13, 2025Time:      6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations"... Read more


iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. iRhythm’s management is scheduled to present on Monday, January 13, 2025, at 4:30 p.m. Pacific Time/7:30 p.m. Eastern Time. Interested parties... Read more


Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device

GOLETA, Calif. / Dec 30, 2024 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company’s ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. SIMEOX 200 is the next-generation... Read more


Treace Medical Concepts Expands Reach into High-Volume Osteotomy Market with Second MIS Osteotomy Platform, Percuplasty™ Percutaneous 3D Bunion Correction® Procedure

PONTE VEDRA, Fla., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the limited market release and first surgical cases utilizing the Percuplasty™ Percutaneous 3D Bunion Correction®... Read more


Inspire Medical Systems to Present at 43rd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Inspire is scheduled to present at 11:15 a.m. Eastern Time. The presentation... Read more


Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

QUEENSBURY, N.Y. / Dec 30, 2024 / Business Wire / Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August... Read more


Inotiv Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares.... Read more


Vivos’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in veterinary cancer care, and expanding its network of certified clinics across the U.S. IsoPet® 2024: A Year of Innovation and Expansion In 2024, IsoPet® cemented its position as a leader in minimally invasive animal cancer treatments, achieving key milestones in growth and inno... Read more


CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s... Read more


AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for RECELL GO® mini. As a line extension of the RECELL GO system, the RECELL GO mini disposable cartridge is designed specifically... Read more


Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin’s new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS). This AI ecosystem is designed to... Read more


Vivos Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial

Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies. This initial trial in India closely aligns with the protocol designed for... Read more


Varex Imaging Announces Closing of Private Offering of $125 Million of Senior Secured Notes

SALT LAKE CITY / Dec 23, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has closed its private offering (the “Offering”) of $125 million aggregate principal amount of 7.875% senior secured notes due 2027 (the “notes”) at an offering price of 101.5% of the principal amount thereof, plus accrued interest from and including October 15, 2024. “We are pleased to have successfully closed the offering of additional senior secured notes,”... Read more


Bionano Genomics Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis

In the largest study to date of bone and soft tissue tumors, OGM detected 100% of the variants found by multiple standard techniques, including karyotyping, fluorescent in-situ hybridization (FISH) & gene fusion assays OGM was also more sensitive, including detection of diagnostic or pathogenic variants missed by karyotype in 74% (14/19) of cases that failed or were negative by karyotyping When OGM results and next-generation sequencing (NGS) results were combined,... Read more


Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

Assuming successful validation, the Company currently expects to launch the pipeline test by the end of 2025 FRIENDSWOOD, Texas / Dec 23, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis (AD) who are seeking systemic treatment. Based on preliminary... Read more


Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif. / Dec 23, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive,... Read more